Table 1

Analysis of the effects of DAC pretreatment on the drug sensitivity of MMR-deficient A2780/cp70 and MMR-proficient CP70-ch3 xenografts

TreatmentTime to double initial tumor volume (days)a
A2780/cp70CP70-ch3
Control2.4 ± 0.22.9 ± 0.2
DAC (5 mg/kg× 3)2.5 ± 0.33.3 ± 0.4
Carboplatin (80 mg/kg)2.9 ± 0.25.4 ± 0.2
DAC+ carboplatin6.1 ± 0.55.6 ± 0.2
Cisplatin (6 mg/kg)2.9 ± 0.25.1 ± 0.2
DAC+ cisplatin6.0 ± 0.36.1 ± 0.2
Temozolomide (200 mg/kg)2.1 ± 0.24.7 ± 0.4
DAC+ temozolomide3.6 ± 0.24.6 ± 0.4
Epirubicin (10 mg/kg)4.3 ± 0.44.8 ± 0.5
DAC+ Epirubicin6.0 ± 0.65.3 ± 0.7
Taxol (15 mg/kg)4.5 ± 0.25.2 ± 0.4
DAC+ Taxol4.8 ± 0.65.2 ± 0.03
  • a Growth delay is quantified as the time taken for the tumor to double the initial volume (day 0), and the results are the mean ± SE of six mice. NS, not significant.

  • b P < 0.001.

  • c P < 0.05. NS b b b c NS NS NS c NS NS NS